MedPage Today (9/12, Monaco) reports, “Care for new depression was more commonly delivered by primary care providers (PCPs) than psychiatric” clinicians, investigators concluded in findings presented in a poster at Psych Congress 2023. The “review of adults newly diagnosed with major depressive disorder, 16,987 patients were under the care of a PCP compared with 1,780 who were managed by a psychiatrist at the time of diagnosis, and only 6.2% of PCP-managed patients transitioned to a psychiatrist for their care,” the study found.

Related Links:

— MedPage Today (requires login and subscription)

According to HealthDay (9/12, Mozes), “new research indicates that the more inactive seniors are, the higher their risk for dementia,” investigators concluded after examining “the onset of dementia among nearly 50,000” citizens of the UK who “were at least 60 years old when information about typical daily activity routines was entered into the UK Biobank database at some point between 2006 and 2010.” The study revealed that “seniors who clocked 12 hours a day of inactivity – be it at one stretch, or over 24 hours – saw their risk for dementia spike by 63%,” while “those who sat around for 15 hours a day had a stunning 320% increase in dementia risk.” The findings were published in JAMA.

Related Links:

— “Dementia Risk Rises as Activity Rates Fall,”Alan Mozes, HealthDay, September 12, 2023

According to MedPage Today (9/12, DePeau-Wilson), psychiatric care professionals “most often ranked the side effect profile of long-acting injectables (LAIs) for schizophrenia as the top consideration when prescribing the antipsychotics to patients,” researchers concluded in the findings of a 380-respondent, “survey-based study” presented in a poster at Psych Congress 2023. Among those respondents, “33% cited the safety/tolerability profile as key when selecting an LAI, with 16% to 21% of the respondents citing patient preference, the particular molecule in the LAI, access, or product attributes like dosing intervals or injection site as most important.”

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (9/11, DePeau-Wilson) reports, “Every-six-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) for schizophrenia was effective and safe up to three years, researchers reported” in “an intention-to-treat analysis that included 121 patients.” The study revealed that “95.9% on the twice-a-year dose of the atypical antipsychotic remained relapse-free.” The findings were presented in a poster at Psych Congress 2023.

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (9/11, DePeau-Wilson) reports, “People with narcolepsy frequently had mood and pain comorbidities that complicated diagnosis and treatment plans,” investigators concluded. In “a propensity-matched cohort analysis of more than 4,000 individuals,” researchers found that “people with narcolepsy were more than twice as likely to be diagnosed with depression” or “chronic pain syndrome.” The findings were presented at Psych Congress 2023.

Related Links:

— MedPage Today (requires login and subscription)

Healio (9/11, Weldon) reports, “Both victims and perpetrators of cyberbullying are more likely than other youths to experience eating disorder symptoms,” researchers concluded after studying “responses from 10,258 adolescents in the U.S. aged 10 to 14 years who answered questions about whether they had experienced cyberbullying – as a victim or perpetrator – and whether they had experienced eating disorder symptoms.” The findings were published online Sept. 6 in the International Journal of Eating Disorders.

Related Links:

— “Eating disorders affect victims and perpetrators of cyberbullying,”Rose Weldon, Healio, September 11, 2023

MedPage Today (9/9, Monaco) reported, “Youth with attention-deficit/hyperactivity disorder” (AD/HD) “saw mildly different growth trajectories with certain popular medications, researchers reported” in findings presented in a poster at Psych Congress 2023. The study revealed that when “compared with youth prescribed lisdexamfetamine dimesylate (LDX; Vyvanse), those who took delayed release/extended-release methylphenidate (DR/ER-MPH; Jornay PM) saw a greater weight trajectory in the first year after starting treatment.” Included in the final study sample were “83 patients on DR/ER-MPH, 240 on OROS MPH, and 403 on LDX.”

Related Links:

— MedPage Today (requires login and subscription)

Newsday (NY) (9/10, Spangler) reports, “More than 20 years after the Sept. 11 attacks, the volume of research on responders and survivors is substantial and growing, yielding sometimes unexpected, potentially powerful revelations about the long-term physical and mental effects of exposure to disaster.” The National database of the National Library of Medicine, PubMed, “lists roughly 1,300 scientific papers about the World Trade Center with close to 60 published in the last year alone.” Some of the most recent “papers examine links between exposure to what doctors have called the ‘toxic cocktail’ of gas and dust at Ground Zero and cancer, pulmonary and cardiovascular conditions, along with trends in substance use and post-traumatic stress disorder.”

Related Links:

— “9/11 first responders health: Study of how Ground Zero exposure affected workers yields powerful results, Newsday , September 10, 2023

CNN (9/8, Musa) reported, “The 988 Suicide and Crisis Lifeline will now be available to the millions of people across the US who use American Sign Language (ASL), according to” HHS. These “ASL services launched” Sept. 8 “will be available for callers who are deaf, deaf-blind or hard of hearing using a videophone,” and “callers can now be connected to a 988 Lifeline counselor trained in ASL by clicking on the ‘ASL Now’ button on 988lifeline.org and following the prompts.”

Related Links:

— “988 mental health crisis line launches American Sign Language services for callers who are deaf and hard of hearing,”Amanda Musa, CNN, September 8, 2023

Bloomberg Law (9/7, Lopez, Subscription Publication) reports that on Thursday, the administration “proposed regulatory revisions to curb disability discrimination in government-funded programs, aiming to update a decades-old regulation that is out of step with the Americans With Disabilities Act and other federal laws.” The HHS “Department’s Office for Civil Rights previously weighed issuing guidance on the matter,” but “the OCR, the administration arm that issued the proposed rule, said on Reginfo.gov that ‘not taking regulatory action could result in continued discrimination, inequitable treatment and even untimely deaths of people with disabilities.’”

Related Links:

— “Updated Disability Protections Proposed by Biden HHS Agency (2),”Ian Lopez , Bloomberg Law, September 7, 2023